Enduring Material

• Relate the effect of the Mainstreaming Addiction Treatment Act and the DEA 30-day post teleprescribing rule on buprenorphine access, nationally and in Michigan.
• Describe common barriers encountered by patients and pharmacists when filling buprenorphine prescriptions for OUD.
• Identify specific strategies for resolving pharmacy-level barriers to buprenorphine access, including interprofessional collaboration and patient communication.

Post X-waiver: Improving Buprenorphine Access at the Community Pharmacy

• Vicki Tutag-Lehr, PharmD

• MyMichigan Health designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• MyMichigan Health designates this enduring material for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Victoria Tutag-Lehr, PharmD has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Victoria Tutag-Lehr, PharmD has indicated the presentation may include discussion of any off-label uses of a product. Explanation Given: Doses of buprenorphine exceeding FDA daily maximum for OUD

• MyMichigan Health is accredited by The Michigan State Medical Society to provide continuing medical education for physicians.

100 %

2/29/2024